<DOC>
	<DOC>NCT02569515</DOC>
	<brief_summary>This study will evaluate the tolerability, and effect on quality of life, in patients receiving multi-dose NeoRecormon administered by RecoPen in predialysis patients with chronic renal anemia. The anticipated time on study treatment is 10 months, and the target sample size is 60 individuals.</brief_summary>
	<brief_title>A Study of Epoetin Beta (NeoRecormon) in Predialysis Patients With Renal Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Adult patients 1865 years of age Chronic renal failure (Stages IIII) No previous epoetin therapy Poorly controlled hypertension History or evidence of malignancy Relevant acute or chronic bleeding (requiring therapy) within 3 months before study drug Women who are pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>